1) anticoagulation factor
抗凝因子
1.
In addition to the generally well-accepted risk factors,such as hyperlipemia,hypertension,obesity,coagulation and anticoagulation factors have been reported to be related with arterial thrombosis.
动脉血栓是一种多因素的疾病,除了常见的高血脂、高血压、肥胖等公认危险因素外,凝血、抗凝因子与动脉血栓的关系也相继见于报道,该文就凝血、抗凝因子基因多态性与动脉血栓的关系作一综述。
2) Lupus antithrombin
狼疮抗凝因子
3) anticoagulant
抗凝
1.
Study of changes of procoagulant,anticoagulant and fibrinolysis in patients withdeep vein thrombosis pretherapy between posttherapy;
下肢深静脉血栓形成患者溶栓前后凝血、抗凝和纤溶活性改变的研究
2.
Anticoagulant treatment on chronic non-valvalar atrial fibrillation in the elderly patients;
老年慢性非瓣膜房颤患者的抗凝治疗
3.
The effect of anticoagulant and thrombolytic therapy on arterial blood gas with acute pulmonary thromboembolism;
抗凝与溶栓治疗对急性肺血栓栓塞症患者血气的影响
4) anticoagulation
抗凝
1.
Anticoagulation of Warfarin Therapy in Patients After Mechanical Valve Implantation;
心脏机械瓣膜置换术后华法林抗凝观察
2.
Observation of Coagulation-anticoagulation and Fibrinolytic System Function in Abnormal Humour Syndrome Patients with Coronary Heart Disease;
异常体液型冠心病患者凝血、抗凝和纤溶系统功能的变化
3.
Study on the Association between the Maintenance Dose of Warfarin Anticoagulation Therapy and the Genetic Mutation of Cytochrome P450 (CYP2C9);
华法林抗凝治疗维持剂量与CYP2C9基因突变的关系
5) Anti-coagulation
抗凝
1.
Objective To investigate the change of the blood coagulation, fibrinolysis and anti-coagulation system indexes in patients with chronic pulmonary heart disease during acute stage and recovery stage.
目的研究慢性肺心病患者急性期和恢复期凝血、纤溶和抗凝指标的变化。
2.
Forty-two cases received surgery in addition to thrombolytic therapy,anti-coagulation and vasodilatation,and 5 cases were treated with drugs only.
4 2例行外科手术加抗凝、溶栓、扩血管治疗。
6) anticoagulation
抗凝血
1.
Preparation and anticoagulation evaluation of emodin/poly(lactic acid) composite films;
大黄素/聚乳酸物复合薄膜的制备及抗凝血研究
2.
Relationship between site of sulfate groups in cellulose sulfate and their anticoagulation activity;
硫酸酯基的位置与纤维素硫酸酯抗凝血活性关系
3.
Recent studies on the anticoagulation and antithrombosis pharmacology of polysaccharides in China;
国内抗凝血、抗血栓多糖的药理研究进展
参考词条
补充资料:正常人白细胞转移因子 , 白细胞转移因子,转移因子
药物名称:转移因子
英文名:Transfer Factor
别名: 正常人白细胞转移因子 , 白细胞转移因子,转移因子
外文名:Transfer Factor ,TF
适应症: 为细胞免疫反应增强剂,能将细胞免疫活性转移给受体,以提高受体的免疫功能。
临床上用于治疗某些抗生素难以控制的病毒性或酶菌性细胞内感染(如带状皰疹、流行性乙型脑炎、白色念珠菌感染等)。对恶性肿瘤可作为辅助治疗剂,对自体免疫性疾病也有一定治疗作用。
用量用法:
一般采用皮下注射,注于上臂内侧或大腿内侧腹股沟下端,1次注射1支,每周1~2次,1个月后改为每2周1次。对带状疱疹,一般只需注射1次。
规格: 注射液:每支2ml,相当于1×1000000000白细胞提取物(上海产),北京产则相当于5~10×1000000000.
注:严禁静脉给药.
类别:免疫调节剂
英文名:Transfer Factor
别名: 正常人白细胞转移因子 , 白细胞转移因子,转移因子
外文名:Transfer Factor ,TF
适应症: 为细胞免疫反应增强剂,能将细胞免疫活性转移给受体,以提高受体的免疫功能。
临床上用于治疗某些抗生素难以控制的病毒性或酶菌性细胞内感染(如带状皰疹、流行性乙型脑炎、白色念珠菌感染等)。对恶性肿瘤可作为辅助治疗剂,对自体免疫性疾病也有一定治疗作用。
用量用法:
一般采用皮下注射,注于上臂内侧或大腿内侧腹股沟下端,1次注射1支,每周1~2次,1个月后改为每2周1次。对带状疱疹,一般只需注射1次。
规格: 注射液:每支2ml,相当于1×1000000000白细胞提取物(上海产),北京产则相当于5~10×1000000000.
注:严禁静脉给药.
类别:免疫调节剂
说明:补充资料仅用于学习参考,请勿用于其它任何用途。